Search Results - "Ondovik, Michael"

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Richardson, Paul G., Schlossman, Robert L., Alsina, Melissa, Weber, Donna M., Coutre, Steven E., Gasparetto, Cristina, Mukhopadhyay, Sutapa, Ondovik, Michael S., Khan, Mahmudul, Paley, Carole S., Lonial, Sagar

“…Panobinostat is an oral pan-deacetylase inhibitor that synergizes with bortezomib to inhibit both the aggresome and proteasome pathways in preclinical studies…”
Get full text

Analysis of the Role of Plasma 25‐Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer by Von Hoff, Daniel D., Cridebring, Derek, Tian, Olivia Yu, Han, Haiyong, Bhore, Rafia, Franco, Twyla, Ondovik, Michael S., Louis, Chrystal U.

“…Background We examined overall survival (OS) outcomes based on plasma 25‐hydroxyvitamin D [25(OH)D] levels in this post hoc analysis of the phase III MPACT…”
Get full text

Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis by DeAngelo, Daniel J., Mesa, Ruben A., Fiskus, Warren, Tefferi, Ayalew, Paley, Carole, Wadleigh, Martha, Ritchie, Ellen K., Snyder, David S., Begna, Kebede, Ganguly, Siddhartha, Ondovik, Michael S., Rine, Jessica, Bhalla, Kapil N.

“…Summary Myelofibrosis (MF) is a Philadelphia chromosome–negative stem cell myeloproliferative neoplasm (MPN) associated with cytopenias, splenomegaly,…”
Get full text

A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab -Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer by Sahai, Vaibhav, Saif, M. Wasif, Kalyan, Aparna, Philip, Philip A., Rocha-Lima, Caio M., Ocean, Allyson, Ondovik, Michael S., Simeone, Diane M., Banerjee, Sibabrata, Bhore, Rafia, Louis, Chrystal U., Picozzi, Vincent

“…Purpose: To evaluate safety and preliminary efficacy of metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in…”
Get full text

Peginterferon α-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon α-2b plus ribavirin: A pilot study of efficacy and safety by HERRINE, Steven K, BROWN, Robert S, BERNSTEIN, David E, ONDOVIK, Michael S, LENTZ, Ellen, TE, Helen

“…There are no established therapeutic regimens for hepatitis C virus (HCV) patients who relapse following treatment with interferon α-2b and ribavirin or those…”
Get full text

Line of therapy (LOT) definition impacts second-line (2L) survival duration in a metastatic pancreatic cancer (mPCa) electronic health record database by Fish, Susan Meredith, Flick, E. Dawn, Swern, Arlene S., Jiang, Ruiyun, Jirau-Lucca, Gilbert, Ondovik, Michael S., Huang, Jian Hua, Louis, Chrystal Ursula

“…Abstract only 300 Background: Establishing an accurate LOT definition in real-world data (RWD) oncology studies is critical for measuring the effects of…”
Get full text

A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer by Picozzi, Vincent, Sahai, Vaibhav, Simeone, Diane, Rocha Lima, Caio, Ocean, Allyson, Philip, Philip, Saif, Wasif, Kalyan, Aparna, Ondovik, Michael, Shiansong Li, Jack, Louis, Chrystal

Get full text

Treatment patterns and clinical outcomes in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: Analysis of US electronic health records from the Flatiron Health Database by Flick Elizabeth, Dawn, Shiansong Li, Jack, Jirau-Lucca, Gilbert, Ondovik, Michael, Nifenecker, Melissa, Fish, Susan, Liu, Helen, Hua Huang, Jian, Swern, Arlene, Louis, Chrystal

Get full text

P-286Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study by Vincent, Picozzi, Caio, Rocha Lima, Vaibhav, Sahai, Diane, Simeone, Allyson, Ocean, Philip, Philip, Wasif, Saif, Aparna, Kalyan, Michael, Ondovik, Jack, Shiansong Li, Victoria, Manax

Get full text

P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study by Vincent, Picozzi, Caio, Rocha Lima, Vaibhav, Sahai, Diane, Simeone, Allyson, Ocean, Philip, Philip, Wasif, Saif, Aparna, Kalyan, Michael, Ondovik, Jack, Shiansong Li, Victoria, Manax

Get full text

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma by Richardson, Paul G., Schlossman, Robert L., Alsina, Melissa, Weber, Donna M., Coutre, Steven E., Gasparetto, Cristina, Mukhopadhyay, Sutapa, Ondovik, Michael S., Khan, Mahmudul, Paley, Carole S., Lonial, Sagar

“…Multiple myeloma (MM) remains an incurable disease, with a high unmet need for patients (pts) in the relapsed and refractory setting. The prognosis is…”
Get full text

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma by Richardson, Paul G., Alsina, Melissa, Weber, Donna, Coutre, Steven E., Lonial, Sagar, Gasparetto, Cristina, Mukhopadhyay, Sutapa, Ondovik, Michael, Khan, Mahmudul, Paley, Carole, Schlossman, Robert

“…Abstract 1852 There are limited treatment options for patients (pts) with multiple myeloma (MM) whose disease is refractory to bortezomib (BTZ) and are…”
Get full text

Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2) by Alsina, Melissa, Richardson, Paul Gerard Guy, Schlossman, Robert L., Weber, Donna M., Coutre, Steven E., Gasparetto, Cristina, Mukhopadhyay, Sutapa, Ondovik, Michael S., Khan, Mahmudul H, Paley, Carole S., Lonial, Sagar

“…Abstract only 8531 Background: In PANORAMA 2, PAN + BTZ + DEX recaptured responses in heavily pretreated pts with BTZ-refractory MM; overall response rate…”
Get full text

Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2) by Richardson, Paul G., Alsina, Melissa, Weber, Donna M., Coutre, Steven E., Lonial, Sagar, Gasparetto, Cristina, Warsi, Ghulam, Ondovik, Michael, Mukhopadhyay, Sutapa, Snodgrass, Susan, Schlossman, Robert

“…Abstract 814▪FN2▪This icon denotes a clinically relevant abstract Patients with refractory multiple myeloma (MM) have limited treatment options and an…”
Get full text

PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma by Alsina, Melissa, Schlossman, Robert L., Weber, Donna M., Coutre, Steven E., Lonial, Sagar, Gasparetto, Cristina, Warsi, Ghulam, Ondovik, Michael S., Mukhopadhyay, Sutapa, Paley, Carole S., Richardson, Paul Gerard Guy

“…Abstract only 8012 Background: Patients (pts) with multiple myeloma (MM) refractory to bortezomib (BTZ) and an immunomodulatory drug have limited treatment…”
Get full text

A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis by DeAngelo, Daniel J, Tefferi, Ayalew, Fiskus, Warren, Mesa, Ruben A., Paley, Carole S., Wadleigh, Martha, Snyder, David S., Begna, Kebede, Ondovik, Michael S., Rine, Jessica, Bhalla, Kapil N.

“…Abstract 630 Medical treatment options for myelofibrosis (MF) are palliative in nature. Short of allogeneic stem cell transplantation, no therapies are…”
Get full text

Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety by Herrine, Steven K, Brown, Jr, Robert S, Bernstein, David E, Ondovik, Michael S, Lentz, Ellen, Te, Helen

“…There are no established therapeutic regimens for hepatitis C virus (HCV) patients who relapse following treatment with interferon alpha-2b and ribavirin or…”
Get full text

Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne by DiGiovanna, John J., Langman, Craig B., Tschen, Eduardo H., Jones, Terry, Menter, Alan, Lowe, Nicholas J., Eichenfield, Lawrence, Hebert, Adelaide A., Pariser, David, Savin, Ronald P., Smith, Stacy R., Jarratt, Michael, Rodriguez, David, Chalker, Dan K., Kempers, Steven, Ling, Mark, Rafal, Elyse S., Sullivan, Sabra, Kang, Sewon, Shah, Leena P., Wu, Emily, Newhouse, Julie, Pak, Jonathan, Eberhardt, Douglas R., Bryce, Graeme F., McLane, John A., Ondovik, Michael, Chin, Catherine, Khoo, Ko-Chin, Rich, Phoebe

“…Adverse changes in bone have been reported for patients undergoing high-dose, long-term (several years) isotretinoin therapy for disorders of cornification…”
Get full text

Peginterferon [alpha]-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon [alpha]-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety by Herrine, Steven K, Brown, Robert S, Bernstein, David E, Ondovik, Michael S, Lentz, Ellen, Te, Helen

“…There are no established therapeutic regimens for hepatitis C virus (HCV) patients who relapse following treatment with interferon α-2b and ribavirin or those…”
Get full text